Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

92.93 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

MERCK & CO. INC. (NYSE:MRK) – A Strong Value Investment with Undervalued Potential ↗

August 16, 2025

Merck & Co. (MRK) is a strong value stock with low P/E, high earnings, stable finances, and a reliable dividend—ideal for long-term investors.

Via Chartmill

Branded Pharmaceuticals Stocks Q2 In Review: Merck (NYSE:MRK) Vs Peers

August 14, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck (NYSE:MRK) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Dividend Investor Earning $5,200 A Month Shares His Top 7 Stock Picks – 'Getting Dividend is the Biggest Joy in My Life' ↗

August 14, 2025

Via Benzinga

3 Magnificent S&P 500 Dividend Stocks Down Roughly 26% to 60% to Buy and Hold Forever ↗

August 13, 2025

A good stock is an even better buy when it's on sale.

Via The Motley Fool

Topics Intellectual Property Stocks

If You're In Your 20's, Consider Buying These 3 Healthcare Stocks ↗

August 13, 2025

If you have decades to go before you retire, you want to make sure you own companies that know how to survive and thrive.

Via The Motley Fool

Topics Retirement

MRK Q2 Deep Dive: Pipeline Strength and New Product Launches Highlight Transition Period

August 13, 2025

Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% year on year to $15.81 billion. The company’s outlook for the full year was...

Via StockStory

Merck, Pfizer-Backed Therapy Improves Outcomes For Cisplatin-Ineligible Bladder Cancer Patients ↗

August 12, 2025

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for cisplatin therapy.

Via Benzinga

KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

August 12, 2025

From Merck & Co., Inc.

Via Business Wire

3 Reasons We’re Fans of Merck (MRK)

August 12, 2025

Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is disappointing considering the S&P 500 has climbed by 5.4%. This may have investors...

Via StockStory

Topics Stocks Supply Chain

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x ↗

August 11, 2025

The company said Cylembio plus Keytruda demonstrated clinical improvement in progression-free survival compared to Keytruda alone, but statistical significance was “narrowly” missed.

Via Stocktwits

IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year ↗

August 11, 2025

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most subgroups.

Via Benzinga

2 Magnificent Stocks to Buy That Are Near 52-Week Lows ↗

August 10, 2025

These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

Via The Motley Fool

Topics Intellectual Property

3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August ↗

August 10, 2025

One reliable high-yielder, one dividend growth stock, and one turnaround story for dividend lovers in August.

Via The Motley Fool

Topics Economy Intellectual Property

2 Cash-Producing Stocks for Long-Term Investors and 1 We Brush Off

August 08, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Political Tremors Rattle Markets: The Profound Impact of U.S. Elections and Tariff Shocks

August 07, 2025

The intricate dance between political shifts and financial markets has once again taken center stage, demonstrating the profound influence of electoral outcomes and subsequent policy decisions on...

Via MarketMinute

Topics Economy Government Stocks

Is It Time to Buy Biotech Stocks? ↗

August 06, 2025

A surge in private market investment has investors wondering: Is it time to bet bigger on biotech?

Via The Motley Fool

MERCK & CO. INC. (NYSE:MRK): A Top Dividend Stock with Strong Profitability and Financial Stability ↗

August 06, 2025

Merck & Co. (MRK) is a top dividend stock with a 4.06% yield, strong profitability, and solid financials, making it a reliable choice for income investors.

Via Chartmill

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

August 06, 2025

Their steep payouts make them worth a look, but a big dividend doesn't inherently make a stock worth owning.

Via The Motley Fool

Topics Stocks World Trade

Merck (MRK) Q2 2025 Earnings Call Transcript ↗

August 04, 2025

Via The Motley Fool

Topics Earnings

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

Via Investor Brand Network

Topics Government

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

August 04, 2025

EQNX::TICKER_START (NASDAQ:SNGX),(NYSE:PFE),(NYSE:MRK),(NYSE:BMY),(NASDAQ:INSM) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Government

This Biotech Stock Could Soar on Upcoming Clinical Data ↗

August 04, 2025

This weight loss drugmaker may be significantly undervalued right now.

Via The Motley Fool

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

August 04, 2025

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

3 High-Yielding Dividend Stocks That Are Trading Near Their 52-Week Lows ↗

August 02, 2025

If you are looking for dividend stocks, a good place to start is with unloved stocks like these, with yields of up to 6.4%.

Via The Motley Fool

Topics Intellectual Property

Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗

August 01, 2025

President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences.

Via Benzinga

Topics Government

Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗

July 31, 2025

Via Stocktwits

Topics Government

Investing $2,000 in Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth Nearly $135,000 Today ↗

July 31, 2025

These stocks have all surged more than 1,000% since August 2020.

Via The Motley Fool

Topics Artificial Intelligence

Cautious Optimism As Merck Leans On Oncology Amid Gardasil Vaccine Concerns ↗

July 30, 2025

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove investor interest.

Via Benzinga

Topics Earnings

Why Merck Stock Slipped Today ↗

July 29, 2025

A change in full-year guidance by management wasn't particularly welcome.

Via The Motley Fool

Is Merck & Co Gaining or Losing Market Support? ↗

July 29, 2025

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

All News about Merck & Co

Starting at $3.75/week.

Subscribe Today